Idioma:

Precision oncology in metastatic colorectal cancer - from biology to medicine

Di Nicolantonio, Federica ; Vitiello, Pietro Paolo ; Marsoni, Silvia ; Siena, Salvatore ; Tabernero, Josep ; Trusolino, Livio ; Bernards, Rene ; Bardelli, Alberto

Nature reviews. Clinical oncology, 2021-08, Vol.18 (8), p.506-525 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por

Enviar para

Título:
Precision oncology in metastatic colorectal cancer - from biology to medicine
Autor: Di Nicolantonio, Federica ; Vitiello, Pietro Paolo ; Marsoni, Silvia ; Siena, Salvatore ; Tabernero, Josep ; Trusolino, Livio ; Bernards, Rene ; Bardelli, Alberto
Assuntos: Analysis ; Animals ; Biology ; Breast cancer ; Care and treatment ; Clinical trials ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - pathology ; Colorectal Neoplasms - therapy ; Complications and side effects ; Drug therapy ; Drugs ; Evidence-Based Medicine - methods ; Evidence-Based Medicine - trends ; Gene mutations ; Genetic aspects ; Health aspects ; Humans ; Medical research ; Medicine, Experimental ; Melanoma ; Metastases ; Metastasis ; Neoplasm Metastasis ; Oncogenes ; Oncology ; Patients ; Precision medicine ; Precision Medicine - methods ; Precision Medicine - trends ; Solid tumors ; Translational Research, Biomedical - methods ; Translational Research, Biomedical - trends ; Tumors
É parte de: Nature reviews. Clinical oncology, 2021-08, Vol.18 (8), p.506-525
Descrição: Remarkable progress has been made in the development of biomarker-driven targeted therapies for patients with multiple cancer types, including melanoma, breast and lung tumours, although precision oncology for patients with colorectal cancer (CRC) continues to lag behind. Nonetheless, the availability of patient-derived CRC models coupled with in vitro and in vivo pharmacological and functional analyses over the past decade has finally led to advances in the field. Gene-specific alterations are not the only determinants that can successfully direct the use of targeted therapy. Indeed, successful inhibition of BRAF or KRAS in metastatic CRCs driven by activating mutations in these genes requires combinations of drugs that inhibit the mutant protein while at the same time restraining adaptive resistance via CRC-specific EGFR-mediated feedback loops. The emerging paradigm is, therefore, that the intrinsic biology of CRC cells must be considered alongside the molecular profiles of individual tumours in order to successfully personalize treatment. In this Review, we outline how preclinical studies based on patient-derived models have informed the design of practice-changing clinical trials. The integration of these experiences into a common framework will reshape the future design of biology-informed clinical trials in this field.
Editor: England: Nature Publishing Group
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Precision oncology in metastatic colorectal cancer - from biology to medicine

Di Nicolantonio, Federica ; Vitiello, Pietro Paolo ; Marsoni, Silvia ; Siena, Salvatore ; Tabernero, Josep ; Trusolino, Livio ; Bernards, Rene ; Bardelli, Alberto

England: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.